These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 468738)

  • 1. Antibacterial activity of heneicomycin.
    Frost BM; Valiant ME; Dulaney EL
    J Antibiot (Tokyo); 1979 Jun; 32(6):626-9. PubMed ID: 468738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of efrotomycin.
    Frost BM; Valiant ME; Weissberger B; Dulaney EL
    J Antibiot (Tokyo); 1976 Oct; 29(10):1083-91. PubMed ID: 994327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of cross-resistance between efrotomycin and antibacterial agents used in the therapy of human and animal infections.
    Jacks TM; Frazier EG; Abruzzo GK; Graham AC; Fromtling RA
    Methods Find Exp Clin Pharmacol; 1989 Nov; 11(11):697-701. PubMed ID: 2695724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heneicomycin, a new antibiotic (A21A): fermentation, isolation, and antibacterial spectrum.
    Zimmerman SB; Chalmers JH; Dewey RS; Stapley EO; Hernandez S
    J Antibiot (Tokyo); 1979 Jun; 32(6):665-6. PubMed ID: 468741
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergism between efrotomycin and bottromycin.
    Frost BM; Valiant ME; Dulaney EL
    J Antibiot (Tokyo); 1979 Oct; 32(10):1046-9. PubMed ID: 528364
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin.
    Landini P; Bandera M; Goldstein BP; Ripamonti F; Soffientini A; Islam K; Denaro M
    Biochem J; 1992 May; 283 ( Pt 3)(Pt 3):649-52. PubMed ID: 1590753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of efrotomycin, ciprofloxacin, and six other antimicrobials against Clostridium difficile.
    Clabots CR; Shanholtzer CJ; Peterson LR; Gerding DN
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):49-52. PubMed ID: 3802745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879.
    Landini P; Bandera M; Soffientini A; Goldstein BP
    J Gen Microbiol; 1993 Apr; 139(4):769-74. PubMed ID: 8515234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-681,217, a new and novel member of the efrotomycin family of antibiotics.
    Kempf AJ; Wilson KE; Hensens OD; Monaghan RL; Zimmerman SB; Dulaney EL
    J Antibiot (Tokyo); 1986 Oct; 39(10):1361-7. PubMed ID: 3781906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of efrotomycin on gain and feed efficiency for pigs from weaning until market weight.
    Foster AG; Baker DH; Cline TR; Cromwell GL; Veum TL; Alva-Valdes R; Ericsson GF
    J Anim Sci; 1987 Oct; 65(4):877-80. PubMed ID: 3667459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antibacterial activities of clarithromycin.
    Ono T; Numata K; Nagate T; Mitsuhashi S; Inoue M
    Chemotherapy; 1996; 42(3):159-69. PubMed ID: 8983882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of antibacterial activities of antibiotics in vitro and in animal models of infection.
    Zak O; Tosch W; Sande MA
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():273-82. PubMed ID: 3980330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluations of the antibiotic efrotomycin.
    Stutz MW; Johnson SL; Judith FR; Miller BM
    Poult Sci; 1983 Aug; 62(8):1612-8. PubMed ID: 6314312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.
    Pallanza R; Berti M; Goldstein BP; Mapelli E; Randisi E; Scotti R; Arioli V
    J Antimicrob Chemother; 1983 May; 11(5):419-25. PubMed ID: 6223907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asparenomycins A, B and C, new carbapenem antibiotics. IV. Antibacterial activity.
    Kimura Y; Motokawa K; Nagata H; Kameda Y; Matsuura S; Mayama M; Yoshida T
    J Antibiot (Tokyo); 1982 Jan; 35(1):32-8. PubMed ID: 7068514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
    Arioli V; Berti M; Carniti G; Randisi E; Rossi E; Scotti R
    J Antibiot (Tokyo); 1981 Aug; 34(8):1026-32. PubMed ID: 7319918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycocinnamoylspermidines, a new class of antibiotics. V. Antibacterial evaluation of the isopropyl derivative of LL-BM123gamma.
    Kuck NA; Redin GS
    J Antibiot (Tokyo); 1978 May; 31(5):405-9. PubMed ID: 670083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioconversion capacity of Streptomyces sp GE44282, a producer of the antibiotics heneicomycin and aurodox.
    Marinelli F; Stella S; Montanini N; Le Monnier F; Cavaletti L; Selva E
    J Ind Microbiol; 1995 Jul; 15(1):49-54. PubMed ID: 7662297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions among antibiotics, bacteria and the human immune system: the clinical relevance of in vitro testing.
    Bergogne-Berezin E
    J Chemother; 1997 May; 9 Suppl 1():109-15. PubMed ID: 9248969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.